サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1722815

抗高脂血症薬の市場規模、シェア、動向、予測：薬剤クラス別、投与経路別、流通チャネル別、地域別、2025年～2033年

Antihyperlipidemic Drugs Market Size, Share, Trends and Forecast by Drug Class, Route of Administration, Distribution Channel, and Region, 2025-2033

出版日
発行
IMARC
ページ情報
英文 149 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
抗高脂血症薬の市場規模、シェア、動向、予測：薬剤クラス別、投与経路別、流通チャネル別、地域別、2025年～2033年
出版日: 2025年05月01日
発行: IMARC
ページ情報: 英文 149 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗高脂血症薬の世界市場規模は2024年に131億米ドルとなりました。今後、IMARC Groupは、同市場が2033年までに186億米ドルに達し、2025年から2033年にかけて3.9%のCAGRを示すと予測しています。現在、北米が市場を独占しており、2024年には32.7％を超える大きな市場シェアを占めています。北米市場は、高脂血症や心血管疾患の高い有病率、高齢化、肥満、座りがちなライフスタイル、不健康な食生活によって活性化されています。旺盛な研究開発投資、高度なヘルスケアインフラ、政府のイニシアティブ、スタチン、PCSK9阻害剤、新規脂質低下薬の採用増加、保険適用などが抗高脂血症薬の市場シェアをさらに押し上げています。

抗高脂血症薬は、血中のコレステロールや様々な脂質の血清レベルを下げるのに役立ちます。抗高脂血症薬は、高コレステロールをコントロールし、特定の病状のリスクを軽減するために、様々な薬と併用することができます。現在、世界中で様々なクラスの薬が販売されており、患者のコレステロール値や基礎疾患、その他の要因に基づいて投与することができます。一般的に入手可能な抗高脂血症薬のには、スタチン、抗高脂血症薬配合剤、胆汁酸分泌抑制剤、コレステロール吸収阻害剤、フィブリン酸誘導体、PCSK9阻害剤などがあります。

抗高脂血症薬の市場動向：

座りがちなライフスタイル、ニコチン中毒、脂肪分の多い食品の大量摂取を原因とする高脂血症の有病率の増加は、抗高脂血症薬の需要を喚起する重要な要因の一つです。さらに、高脂血症は冠動脈疾患（CAD）の開発リスクを高める。その結果、低比重リポ蛋白（LDL）コレステロールとトリグリセリドの高値を低下させ、高比重リポ蛋白（HDL）コレステロールの低値を上昇させる薬剤の必要性が高まっています。これとは別に、コレステロール値が高い子供や様々な脂質異常症の治療にも使用されています。さらに、小児集団における脂質およびリポ蛋白代謝の遺伝的および後天的障害の急増は、入院率や早死率を減少させる抗高脂血症薬の必要性にプラスの影響を与えています。さらに、先進的な新薬が承認されたことで、市場の見通しも良好です。これに加えて、世界中の医薬品化学者がこれらの薬剤のために様々な新しい分子を設計、合成、評価しており、市場の成長に貢献すると予想されます。

本レポートで扱う主な質問

  • 抗高脂血症薬の市場の規模は？
  • 抗高脂血症薬の市場の将来展望は？
  • 抗高脂血症薬の市場を牽引する主要因は何か？
  • 抗高脂血症薬の市場で最大のシェアを占める地域は？
  • 世界の抗高脂血症薬の市場における主要企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の抗高脂血症薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤クラス別

  • スタチン
  • 胆汁酸吸着剤
  • コレステロール吸収阻害剤
  • フィブリン酸誘導体
  • PCSK9阻害剤
  • 併用
  • その他

第7章 市場内訳：投与経路別

  • 経口
  • 静脈内

第8章 市場内訳：流通チャネル別

  • 病院薬局
  • 小売店
  • オンライン小売業者

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amgen Inc.
    • AstraZeneca plc
    • Daiichi Sankyo Company Limited
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A
図表

List of Figures

  • Figure 1: Global: Antihyperlipidemic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Antihyperlipidemic Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Antihyperlipidemic Drugs Market: Breakup by Drug Class (in %), 2024
  • Figure 5: Global: Antihyperlipidemic Drugs Market: Breakup by Route of Administration (in %), 2024
  • Figure 6: Global: Antihyperlipidemic Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Antihyperlipidemic Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Antihyperlipidemic Drugs (Statins) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Antihyperlipidemic Drugs (Statins) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Antihyperlipidemic Drugs (Combination) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Antihyperlipidemic Drugs (Combination) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Antihyperlipidemic Drugs (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Antihyperlipidemic Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Antihyperlipidemic Drugs (Intravenous) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Antihyperlipidemic Drugs (Intravenous) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Antihyperlipidemic Drugs (Retail Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Antihyperlipidemic Drugs (Retail Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Antihyperlipidemic Drugs (Online Retailers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Antihyperlipidemic Drugs (Online Retailers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: North America: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: North America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: United States: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: United States: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Canada: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Canada: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Asia-Pacific: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Asia-Pacific: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: China: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: China: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Japan: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Japan: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: India: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: India: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: South Korea: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: South Korea: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Australia: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Australia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Indonesia: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Indonesia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Europe: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Europe: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Germany: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Germany: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: France: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: France: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: United Kingdom: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: United Kingdom: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Italy: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Italy: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Spain: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Spain: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Russia: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Russia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Latin America: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Latin America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Brazil: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Brazil: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Mexico: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Mexico: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Middle East and Africa: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Middle East and Africa: Antihyperlipidemic Drugs Market: Breakup by Country (in %), 2024
  • Figure 80: Middle East and Africa: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Global: Antihyperlipidemic Drugs Industry: SWOT Analysis
  • Figure 82: Global: Antihyperlipidemic Drugs Industry: Value Chain Analysis
  • Figure 83: Global: Antihyperlipidemic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antihyperlipidemic Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 4: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Antihyperlipidemic Drugs Market: Competitive Structure
  • Table 7: Global: Antihyperlipidemic Drugs Market: Key Players
目次
Product Code: SR112025A5622

The global antihyperlipidemic drugs market size was valued at USD 13.1 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 18.6 Billion by 2033, exhibiting a CAGR of 3.9% during 2025-2033. North America currently dominates the market, holding a significant market share of over 32.7% in 2024. The market in North America is fueled by the high prevalence of hyperlipidemia and cardiovascular diseases, aging populations, obesity, sedentary lifestyles, and unhealthy diets. Strong R&D investments, advanced healthcare infrastructure, government initiatives, rising adoption of statins, PCSK9 inhibitors, and novel lipid-lowering drugs, along with insurance coverage, further fuel antihyperlipidemic drugs market share.

Antihyperlipidemic drugs help lower serum levels of cholesterol and various lipids in the blood. They can be taken with different medications to control high cholesterol and reduce the risk of certain medical conditions. At present, their different classes are available worldwide, which can be given based on the patient's cholesterol profile, underlying disease, and other factors. Some of the commonly available antihyperlipidemic drugs include statins, antihyperlipidemic combinations, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and PCSK9 inhibitors.

Antihyperlipidemic Drugs Market Trends:

The growing prevalence of hyperlipidemia on account of sedentary lifestyles, nicotine addiction, and high consumption of fatty foods represents one of the key factors catalyzing the demand for antihyperlipidemic drugs. Moreover, hyperlipidemia increases the risk of developing coronary artery disease (CAD), which is the most common cause of death among adults worldwide. As a result, there is a rise in the need for these drugs to reduce the high levels of low-density lipoprotein (LDL) cholesterol and triglycerides while increasing the low levels of high-density lipoprotein (HDL) cholesterol. Apart from this, they are used to treat children with high cholesterol levels and various lipid disorders. In addition, a surge in the number of genetic and acquired disorders of lipid and lipoprotein metabolism among the pediatric population is positively influencing the need for antihyperlipidemic drugs to reduce the rates of hospitalization and premature deaths. Furthermore, the approval of new and advanced drugs is creating a favorable outlook for the market. Besides this, medicinal chemists around the world are designing, synthesizing, and evaluating a variety of new molecules for these drugs, which is anticipated to contribute to the growth of the market.

Key Market Segmentation:

Breakup by Drug Class:

  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • PCSK9 Inhibitors
  • Combination
  • Others

Breakup by Route of Administration:

  • Oral
  • Intravenous

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Stores
  • Online Retailers

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.

Key Questions Answered in This Report

  • 1.How big is the antihyperlipidemic drugs market?
  • 2.What is the future outlook of the antihyperlipidemic drugs market?
  • 3.What are the key factors driving the antihyperlipidemic drugs market?
  • 4.Which region accounts for the largest antihyperlipidemic drugs market share?
  • 5.Which are the leading companies in the global antihyperlipidemic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antihyperlipidemic Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Statins
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bile Acid Sequestrants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cholesterol Absorption Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Fibric Acid Derivatives
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 PCSK9 Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Combination
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intravenous
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Stores
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Retailers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Daiichi Sankyo Company Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Merck & Co. Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Novartis AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Sanofi S.A
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials